Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL1290013 | 0.90 | — | — | |
| SCHEMBL1290217 | 0.90 | BRD4 (0.36) | BRD4BRD9PARP10DGAT1SCN9A | |
| Potassium Ion SCHEMBL15261838 | 0.89 | TOP2A (0.38) | — | |
| Potassium Ion SCHEMBL1290141 | 0.87 | — | — | |
| Potassium Ion SCHEMBL12502028 | 0.87 | TOP2A (0.39) | — | |
| SCHEMBL1289972 | 0.86 | KDM4E (0.36) | BRD4BRD9SCN9A | |
| SCHEMBL20083157 | 0.85 | SCN9A (0.34) | DGAT1SCN9A | |
| Potassium Ion SCHEMBL15261608 | 0.84 | ALOX5AP (0.35) | BRD4 | |
| Potassium Ion SCHEMBL12502340 | 0.84 | ALOX5AP (0.35) | BRD4 | |
| SCHEMBL1290124 | 0.83 | TOP2A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3476844-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Emergent Product Development Gaithersburg Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2019-04-11 | — | — | US | disclosed |
| US-10155021-B2 | Antimicrobial 4-oxoquinolizines | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180296555-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2018-10-18 | — | — | US | disclosed |
| EP-2621491-B1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEV GAITHERSBURG INC (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-3312176-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Emergent Product Development Gaithersburg Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170232060-A9 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170209437-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2017-07-27 | — | — | US | disclosed |
| US-20170106045-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2017-04-20 | — | — | US | disclosed |
| US-9403818-B2 | Antimicrobial 4-oxoquinolizines | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2016-08-02 | — | — | US | disclosed |
| EP-3034078-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | Emergent Product Development Gaithersburg Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| US-20150141435-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2015-05-21 | — | — | US | disclosed |
| US-8962842-B2 | 2-pyridone antimicrobial compositions | EVOLVA SA (CH) | 2015-02-24 | — | — | US | disclosed |
| EP-2670410-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Evolva SA (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-20130252882-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EVOLVA SA (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2013-09-19 | — | — | US | disclosed |
| EP-2621491-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | Evolva SA (CH) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012104305-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EVOLVA SA (CH) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012047487-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | BRD4 334/4885BRD9 2041/4885PARP10 3340/4885 |
| US-10155021-B2 | Antimicrobial 4-oxoquinolizines | DCAF15, CUL4A, CUL4B | BRD4 333/4885BRD9 1732/4885PARP10 3349/4885 |
| US-20180296555-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | BRD4 1356/4885BRD9 3344/4885PARP10 347/4885 |
| US-20170106045-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | BRD4 334/4885BRD9 2041/4885PARP10 3340/4885 |
| US-20170232060-A9 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | BRD4 334/4885BRD9 2041/4885PARP10 3340/4885 |
| US-20150141435-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | BRD4 1356/4885BRD9 3344/4885PARP10 347/4885 |
| US-20130252882-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | BRD4 334/4885BRD9 2041/4885PARP10 3340/4885 |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | BRD4 1153/4885BRD9 3560/4885PARP10 406/4885 |
| US-20170209437-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | BRD4 1356/4885BRD9 3344/4885PARP10 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.